Additional European Equity News

Aker BP (AKERBP NO) – Q4 (USD): Revenue 1.9bln (exp. 1.93bln), EBIT 1.2bln (exp. 1.2bln). FY21 dividend 1.9/shr. Multiple key milestones planned for 2022. (Newswires)

AstraZeneca (AZN LN) – Q4/FY (USD): FY21: Revenue 37.4bln (exp. 35.8bln), Core EPS 5.29 (exp. 4.96); board intends to increase the annualised dividend to 2.90 (prev. 2.80) and has approved a second interim dividend for FY21 of 1.97 – total FY21 declared dividend of 2.87. Q4: Core EPS 1.67 (exp. 1.50). Alexion integration activities expected to incur a one-time 2.1bln restructuring cost. FY22 guidance: Total Revenue is expected to increase by a high teens percentage and Core EPS is expected to increase by a mid-to-high twenties percentage. Total Revenue from COVID-19 medicines is anticipated to decline by a low-to-mid twenties percentage; expected decline in Vaxzevria being partially offset by growth in Evusheld. (AstraZeneca)

Ashmore (ASHM LN) - H1 2022 (GBP): Adj. revenue 138.2mln (exp. 156.8mln). Adj. pretax 90.6mln (exp. 106.2mln). (Newswires) 

Atos (ATO FP) - Co. will be reporting a goodwill impairment of around EUR 1.9bln. Co. affirms its FY21 revenue and FCF. (Newswires)

Bilfinger (GBF GY) - FY (EUR): Prellim adj. EBITDA 235mln (exp. 215mln), propose a Dividend of 1.00, alongside a 3.75 special dividend. (Newswires)

Deutsche Boerse (DB1 GY) - Q4 2021 (EUR): Q4 revenue 1.13bln (prev. 1.02bln Y/Y). EBITDA 504mln (exp. 490mln). Net 300mln (prev. 242.3mln). (Newswires)

Delivery Hero (DHER GY) – FY (EUR): Revenue 6.6bln (exp. 6.01bln), GMV 35.4bln (exp. 33-35bln). FY22 guidance: Revenue 9.5-10.5bln (exp. 9.4bln), GMV 44-45bln; outlook to reach a positive adj. EBITDA for the platform business. (Newswires)

KBC (KBC BB) - Q4 2021 (EUR): Revenue EUR 1.89bln (prev. 1.80bln). Net 663mln (prev. 601mln). NII 1.18bln (1.07bln). Net fee and commission 479mln (403mln). (Newswires)

Legal & General (LGEN LN) – Agreed a USD 500mln buy-in with the Heathrow BAA Pension Scheme. (Newswires)

Legrand (LR FP) - FY21 (EUR): Revenue 6.99bln (prev. 6.10bln Y/Y). Net 904mln (prev. 681.2mln Y/Y). FCF +3.9%. Ad. operating profit 1.34bln (prev. 1.24bln Y/Y). (Newswires) 

Mapfre (MAP SM) - FY21 (EUR): Net 765.2mln (exp. 714.9mln). REvenue 27.3bln (prev. 25bln Y/Y). (Newswires) 

Mercedes-Benz Group (MBG GY) - China's Banking Regulator has criticized the Ci's financial unit for violating disclosure rules. (Newswires)

Metro (B4B GY) - Q1 2022 (EUR):  Revenue 7.60bln (exp. 7.20bln). Adj. EBITDA 521mln (prev. 375mln Y/Y). (Newswires) 

Neste (NESTE FH) – Q4 (EUR): Revenue 4.96bln (exp. 4.05bln), Operating Profit 524mln (exp. 416mln). Propose a Dividend of 0.82/shr (exp. 0.80/shr). (Newswires)

Nexi (NEXI IM) - Undertaking a strategic review for the potential sale of Ratepay for EUR 1bln, according to Bloomberg. (Newswires)

Pernod Ricard (RI FP) - H1 2022 (EUR): Sales 5.96bln (exp. 5.87bln), Net Profit 1.39bln (exp. 1.35bln), Profit from Recurring Operations 2.0bln (prev. 1.6bln). Accelerates its share buy-back programme with an additional EUR 250mln. (Newswires)

Prudential (PRU LN) - Mike Wells, Group CEO, intends to retire from his role at the end of March 2022. (Yahoo Finance)

Redrow (RDW LN) - H1 2022 (GBP): Revenue 1.05bln (prev. 1.04bln). Pretax 203mln (prev. 174mln Y/Y). EPS 0.481 (prev. 0.410). (Newswires)

Sanofi (SAN FP) - Olipudase alfa shown to provide sustained improvement across multiple clinical manifestations of ASMD. Seperately, FDA accepts Dupixent® (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis. (Sanofi)

Telecom Italia (TIT IM) - Italy sees KKR's bid for the co. as too low, according to sources cited by Bloomberg. (Newswires) 

TotalEnergies (TTE FP) - Q4 2021 (USD): Adj. Net 6.83bln (exp. 5.93bln). interim dividend 0.66 (exp. 0.66). Co. raised dividend by 5% and plans a USD 2bln share buyback programme in H1. Co. can take full advantage of the favourable environment, particularly in the LNG and electricity sectors. Sees Capex between USD 14-15bln. (TotalEnergies IR) could proceed to more share buybacks in H2 2022 than planned in H1. (Newswires) 

Unilever (ULVR LN) – Q4/FY (EUR): Revenue 52.4bln (exp. 52.08bln), EPS 2.62 (exp. 2.48), Operating profit 8.7bln (exp. 7.35bln), Turnover 52.4bln (prev. 50.7bln). Do not intend to pursue major acquisitions in the foreseeable future. To conduct a share buyback of EUR 3bln over the next two-years. Pricing will remain strong, some impact on volume from this. Q4 underlying sales expectations 4.9% (exp 3.56%). Separately, Lindsell Train, who hold a 1.33% stake, have said they support the CEO’s consideration of a GBP 50bln deal for GlaxoSmithKline’s (GSK LN) Healthcare unit. (Newswires/Times)

Vestas Wind Systems (VWS DC) - FY21 (EUR): Revenue 15.6bln (Co. exp. 15.5-16.5bln). EBIT Margin 3% (Co. exp. 4%). Co. cuts FY dividend. (Cision)

Adyen (ADYEN NA) upgraded to Overweight from Equal Weight at Barclays

Banca BPM (BAMI IM) upgraded to Buy from Hold at HSBC

Engie (ENGI FP) reiterated with Overweight at JPMorgan Chase

Lonza (LONN SW) upgraded to buy from hold at Stifel Nicolaus

MedioBanca (MB IM) downgraded to Hold from Buy at HSBC

Pandora (PNDORA DC) upgraded to Buy from Hold at Kepler Cheuvreux

Pandora (PNDORA DC) upgraded to Buy from Hold at Handelsbanken

Swiss Re (SREN SW) initiated with Sell at Goldman Sachs

10 Feb 2022 - 07:46- Equities- Source: Newsquawk